{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:29:07Z","timestamp":1762918147333,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T00:00:00Z","timestamp":1599350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102469","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T02:32:55Z","timestamp":1598495575000},"page":"102469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets"],"prefix":"10.1016","volume":"46","author":[{"given":"Dominic","family":"Jack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Nolting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102469_bib0001","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1021\/acschemneuro.0c00172","article-title":"SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection","volume":"11","author":"Butowt","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.msard.2020.102469_bib0002","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102469_bib0003","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102469_bib0004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102469_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102192","article-title":"COVID-19 in persons with multiple sclerosis treated with ocrelizumab \u2013 a pharmacovigilance case series","volume":"42","author":"Hughes","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102469_bib0006","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032003","article-title":"Interferon \u03b2 for multiple sclerosis","volume":"8","author":"Jakimovski","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.msard.2020.102469_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102469_bib0008","first-page":"1775","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2020.102469_bib0009","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons \u2013 induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe."},{"key":"10.1016\/j.msard.2020.102469_bib0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102469_bib0011","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3332\/ecancer.2020.1022","article-title":"Associations between immune-suppressive and stimulating drugs and novel COVID-19 - a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.msard.2020.102469_bib0012","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(20)30147-2","article-title":"An Italian programme for COVID-19 infection in multiple sclerosis","volume":"19","author":"Sormani","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102469_bib0013","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.msard.2020.102469_bib0014","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1056\/NEJMp2015897","article-title":"False negative tests for SARS-CoV-2 infection - challenges and implications","volume":"383","author":"Woloshin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102469_bib0015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:55:41Z","timestamp":1761900941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":15,"alternative-id":["S2211034820305447"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102469","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102469"}}